Berry Oncology Pronounces Novel Diagnostic Methodology for Liver Most cancers Achieved Better Accuracy and Sensitivity In comparison with Current Non-Invasive Strategies


BEIJING, February 24, 2021 / PRNewswire / – Berry Oncology Corporation, a subsidiary of Berry Genomics, announced the results of a case-control study of the effectiveness of a novel diagnostic method for detecting hepatocellular carcinoma (HCC) in cirrhotic patients, demonstrating the new model had greater accuracy and sensitivity compared to existing screening methods.

The study published in Cell Research contained both China and the US-based authors and research teams, separated from Prof. Hong-Yang Wang of the National Center for Liver Cancer, Prof. Jin-Lin Hou from Nanfang Hospital, Southern Medical University and Dr. Lin Wu and Dr. Jian Bai of berry oncology. The researchers collected cell-free DNA (cfDNA) samples from a total of 3,234 people, including 2,250 cirrhotic patients (LC), 508 with HCC and 476 healthy controls (CTRL) from 13 hospitals in 11 provinces China.

Scientists used state-of-the-art next-generation sequencing (NGS) technology to obtain genome-wide 5-hydroxymethylcytosine (5-hmc), nucleosome footprint (NF), 5 ‘end motif, and fragmentation profiles of cfDNAs from all enrolled individuals. The researchers then used a logistic regression method to create a weighted diagnostic model based on the performance of these four characteristics.

The novel diagnostic model, called HIFI, achieved a sensitivity of 95.42%, a specificity of 97.83% and an AUC of 0.996 in the study, a higher degree of accuracy in differentiating HCC from cirrhosis than existing diagnostic tests measuring AFP or PIVKA -II. The procedure was also able to detect signs of liver cancer with an accuracy of 93.9% in people who tested negative with an AFP test and with an accuracy of 90.9% in people who had a PIVKA -II test tested negative.

These results can be obtained regardless of a patient’s age, HBV status, Child-Pugh score, BCLC stage, tumor size or AFP status. In addition, the HIFI model can also be used to screen for other serious cancers such as lung cancer.

HCC, the most common form of liver cancer, is the second most common fatal cancer worldwide. Cirrhotic patients are at the highest risk of developing HCC, and early diagnosis contributes to an improved prognosis with the possibility of curative treatment.

“Because of the low accuracy of current diagnostic methods, new non-invasive strategies for the early diagnosis of HCC in patients with cirrhosis are urgently needed,” the study authors say. “The HIFI method demonstrated excellent performance for early-stage HCC diagnosis compared to other non-invasive methods and offers great potential for HCC detection in cirrhotic patients.”

According to Berry Oncology CEO Jun ZhouThe result of this study is a milestone for Berry Oncology in tumor screening and early detection. As a forerunner in the field of genomic screening of cancers in ChinaThis research is consistent with Berry’s strategic path Card will Accelerate Berry’s advances in the early detection of high-risk, high-incidence tumors and can also contribute to similar goals set in China 13. Five year plan.

In addition to Berry Oncology, the study’s authors also come from the National Liver Cancer Center at Shanghai Eastern Hepatobiliary Surgery Hospital in Shanghai, the Memorial Sloan Kettering Cancer Center in new York, Mengchao Hepatobiliary Hospital of Fujian Medical University in Fuzhou, the second hospital of Shandong University in Jinan, Ningbo Hwamei Hospital in Ningbo, Nanfang Hospital in Guangzhou and more.

About Berry Oncology

Berry Oncology was founded in 2017 as a member company of Berry Genomics and focuses on genetic testing in cancer. Driven by the mission of “diagnose all types of cancer early, treat all patients with precision”, we have set up a complete system of genetic testing products and services for cancer patients and high-risk populations, including analysis of the genetic susceptibility of tumors, early detection, as well as accompanying diagnostics, reaction monitoring and prognosis for both targeted purposes as well as for immunotherapies. For cancer early detection, we have launched a number of early detection and early detection clinical research projects covering liver cancer, lung cancer, gynecological cancer, etc. Berry Oncology has three centers (manufacturing, supercomputing, research and development) in Fuzhou and Beijing. We serve and partner with more than 600 Class 3A hospitals across the country and have provided hundreds of thousands of patients with valuable genetic testing.

For more information, please visit:

About Berry Genomics

Founded in May 2010, Berry Genomics is a leader in clinical genomics and life sciences in China. Berry Genomics is dedicated to the research, development and commercialization of genetic testing technologies in clinical applications. Berry Genomics aims to aid in the accurate diagnosis of diseases throughout the human lifecycle and to improve human health.

As a company with strong research and development capabilities, Berry Genomics pioneered the first NGS-based genetic test, NIPT, in China The company currently offers NGS-based testing for many genetic diseases and cancers from prejudice to adulthood. Berry Genomics is a global leader in clinical trials for the early detection of liver cancer. The use of third generation sequencing technology in both clinical and scientific studies is currently being explored.

Berry Genomics employs approximately 1,500 people who are dedicated to developing products and providing services to over 4,000 national and international organizations and institutions, including hospitals, research institutions, universities and companies.

Berry Genomics was listed on the A share market in China since 2017 under the stock number: 000710.

For more information, please visit:

View original content: http: // existing -non-invasive-methods-301234210.html

SOURCE Berry Oncology Corporation


Please enter your comment!
Please enter your name here